Masson S, Masseroli M, Fiordaliso F, Calvillo L, D'Aquila S, Bernasconi R, Garrido G, Torri M, Razzetti R, Bongrani S, Latini R
Department of Cardiovascular Research, Instituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
J Cardiovasc Pharmacol. 1999 Sep;34(3):321-6. doi: 10.1097/00005344-199909000-00001.
Renin-angiotensin-aldosterone and sympathetic nervous systems overactivity play a major role in worsening the extent of heart failure. Attenuation of neurohumoral activation with angiotensin-converting enzyme (ACE) inhibitors and beta-blockers has proven beneficial in congestive heart failure. Because ACE inhibition is a recommended treatment for heart failure, this study was designed to test the effects on neurohumoral activation, hemodynamics, and left ventricular (LV) volume of the combination of an ACE inhibitor (delapril) with a DA2-dopaminergic receptor/alpha2-adrenoceptor agonist (CHF-1024) or a beta1-adrenoceptor antagonist (metoprolol) after a moderate to large myocardial infarction (MI) in rats. MI was induced by left coronary artery ligation in 134 rats, and six were not operated on. After 2 months, the animals with ECG evidence of MI were treated for 1 more month with CHF- 1024, 0.33 mg/kg/day or with metoprolol (10 mg/kg/day), delivered through implanted osmotic minipumps, in addition to delapril (6 mg/kg/day) in the drinking water. Daily urinary excretion of norepinephrine (NE) and circulating concentration were measured. Hemodynamic variables were measured, and three-dimensional morphometric analysis was done on the diastole-arrested hearts to quantify infarct size and LV geometry. In conscious animals, delapril alone or with CHF-1024 or metropolol did not modify heart rate or systolic blood pressure. Both combination treatments, however, significantly reduced heart rate in anesthetized animals compared with the group receiving vehicle. Infarct size was not different between treatments, averaging 20-22% of LV volume. The threefold increase of LV chamber volume in infarcted rats was significantly attenuated by delapril alone or with CHF-1024 or metoprolol (-37 to -44%, p<0.05). Treatment with a combination of the ACEi and CHF-1024 tended to normalize the shape of the LV cavity. Urinary NE excretion was unaffected by delapril alone but was reduced by the addition of CHF-1024 or metoprolol. In conclusion, 1 month of treatment with doses of delapril having no hemodynamic effect, reduced LV volume in a model of chronic heart failure. When CHF-1024 or metoprolol was given with delapril, sympathetic activation decreased with no unwanted effects, such as excessive hypotension.
肾素 - 血管紧张素 - 醛固酮系统和交感神经系统过度活跃在加重心力衰竭程度方面起主要作用。已证明使用血管紧张素转换酶(ACE)抑制剂和β受体阻滞剂减弱神经体液激活对充血性心力衰竭有益。由于ACE抑制是心力衰竭的推荐治疗方法,本研究旨在测试在大鼠中度至大面积心肌梗死(MI)后,ACE抑制剂(地拉普利)与DA2 - 多巴胺能受体/α2 - 肾上腺素能受体激动剂(CHF - 1024)或β1 - 肾上腺素能受体拮抗剂(美托洛尔)联合使用对神经体液激活、血流动力学和左心室(LV)容积的影响。通过结扎左冠状动脉在134只大鼠中诱导MI,6只未进行手术。2个月后,有MI心电图证据的动物除饮用含地拉普利(6mg/kg/天)的水外,再通过植入式渗透微型泵用CHF - 1024(0.33mg/kg/天)或美托洛尔(10mg/kg/天)治疗1个月。测量去甲肾上腺素(NE)的每日尿排泄量和循环浓度。测量血流动力学变量,并对舒张期停搏的心脏进行三维形态计量分析以量化梗死面积和左心室几何形状。在清醒动物中,单独使用地拉普利或与CHF - 1024或美托洛尔联合使用均未改变心率或收缩压。然而,与接受赋形剂的组相比,两种联合治疗均显著降低了麻醉动物的心率。各治疗组之间的梗死面积无差异,平均为左心室容积的20 - 22%。单独使用地拉普利或与CHF - 1024或美托洛尔联合使用可使梗死大鼠左心室腔容积增加三倍的情况显著减轻(-37至-44%,p<0.05)。ACEi与CHF - 1024联合治疗倾向于使左心室腔形状正常化。单独使用地拉普利不影响尿NE排泄,但加入CHF - 1024或美托洛尔可使其降低。总之,在慢性心力衰竭模型中,使用无血流动力学效应剂量的地拉普利治疗1个月可减少左心室容积。当CHF - 1024或美托洛尔与地拉普利联合使用时,交感神经激活减少,且无不良影响,如过度低血压。